Stock AnalizTakeda Pharmaceutical Co. Ltd. TAK
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Takeda Pharmaceutical Co. Ltd. (TAK) is a healthcare company listed in the US with a market value of about $67.7B. In the twelve months to September 30, 2026 it had revenue of $29.4B and net income of $255M, a net margin of 0.9%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is shareholder returns (3/5); the weakest is value (0/5).
Key numbers: a P/E of 306.1, a price to free cash flow of 24.9, 5-year revenue growth of 0% a year, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 79% below the current price.
Score: 1.2 / 5
Checks passed
- 5-year EPS growth above 10% a year
- Positive free cash flow
- Liabilities below 60% of assets
- Pays a dividend
- 20% to 100% of free cash flow returned to shareholders
- Dividend 3 years in a row
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.4B | $28.2B | $30.7B | $28.2B | $30.2B | $29.3B | $28.9B | $30.3B | $18.9B | $16.6B | $15.5B |
| Net income | $255M | -$954M | $722M | $953M | $2.4B | $1.9B | $3.4B | $408M | $1.2B | $1.8B | $1.0B |
| Free cash flow | $2.7B | $3.9B | $5.7B | $3.6B | $6.3B | $8.2B | $8.1B | $5.0B | $2.3B | $2.9B | $1.8B |
| EPS (diluted) | $0.08 | $-0.30 | $0.23 | $0.30 | $0.75 | $0.60 | $1.07 | $0.13 | $0.39 | $0.56 | $0.33 |
| Net margin | 0.9% | -3.4% | 2.4% | 3.4% | 7.9% | 6.5% | 11.8% | 1.3% | 6.5% | 10.6% | 6.6% |
| ROIC | — | — | 1.8% | 1.4% | 3.9% | 3.5% | 4.1% | 0.8% | 1.7% | 7.0% | 6.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Takeda Pharmaceutical Co.’s P/E ratio?
About 306.1, based on the last twelve months of diluted earnings per share (forward P/E about 39.8).
Is Takeda Pharmaceutical Co. stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 79% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Takeda Pharmaceutical Co. pay a dividend?
Yes. The dividend yield is about 2.96%, and it has paid dividends for 9 years in our data.
Is Takeda Pharmaceutical Co. a good stock to buy?
We do not give buy or sell advice. Takeda Pharmaceutical Co. scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.